Chengdu Easton Biopharmaceuticals Co., Ltd. (688513.SS)
CNY 31.24
(-0.13%)
CNY 31.24
(-0.13%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 1.11 Billion | 1.17 Billion | 1.02 Billion | 921.91 Million | 947.23 Million | 768.75 Million |
| Cost of Revenue | 223.27 Million | 196 Million | 143.31 Million | 104.98 Million | 92.32 Million | 87.35 Million |
| Gross Profit | 893.84 Million | 974.5 Million | 879.62 Million | 816.93 Million | 854.9 Million | 681.4 Million |
| Operating Expenses | 652.1 Million | 748.4 Million | 681.81 Million | 626.69 Million | 743.63 Million | 534.05 Million |
| Selling, General and Administrative Expenses | 403.33 Million | 493.11 Million | 485.15 Million | 490.61 Million | 587.72 Million | 427.37 Million |
| Research and Development Expenses | 238.49 Million | 230.78 Million | 200.69 Million | 153.9 Million | 156.57 Million | 124.39 Million |
| Other Expenses | -697.28 Thousand | 24.5 Million | -4.03 Million | -17.82 Million | -665.47 Thousand | -806.81 Thousand |
| Cost and Expenses | 875.38 Million | 944.4 Million | 825.12 Million | 731.67 Million | 835.95 Million | 621.41 Million |
| Operating Income | 241.73 Million | 260.62 Million | 244.15 Million | 198.79 Million | 114.73 Million | 149.13 Million |
| Interest Expense | 3.41 Million | 2.6 Million | 364.14 Thousand | 724.45 Thousand | 171.92 Thousand | 132.61 Thousand |
| Income Tax Expense | 15.06 Million | 15.46 Million | 14.49 Million | 20.88 Million | 7.3 Million | 13.3 Million |
| Earnings before Tax | 241.49 Million | 261.98 Million | 246.91 Million | 199.05 Million | 115.91 Million | 148.32 Million |
| Net Income | 226.57 Million | 246.52 Million | 232.42 Million | 178.16 Million | 108.61 Million | 135.02 Million |
| Earnings Per Share Basic | 1.29 | 2.05 | 1.94 | 1.48 | 0.90 | 1.50 |
| Earnings Per Share Diluted | 1.89 | 2.05 | 1.94 | 1.48 | 0.90 | 1.50 |
| Weighted Average Shares Outstanding | 176.22 Million | 120.09 Million | 120.09 Million | 120.09 Million | 120.09 Million | 90.01 Million |
| Weighted Average Shares Outstanding (Diluted) | 119.88 Million | 120.09 Million | 120.09 Million | 120.09 Million | 120.09 Million | 90.01 Million |
| Gross Margin | 0.80 | 0.83 | 0.86 | 0.89 | 0.90 | 0.89 |
| EBIT Margin | 0.28 | 0.26 | 0.26 | 0.26 | 0.15 | 0.23 |
| Profit Margin | 0.20 | 0.21 | 0.23 | 0.19 | 0.11 | 0.18 |
| EBITDA | 318.28 Million | 324 Million | 281.28 Million | 233.89 Million | 144.03 Million | 173.89 Million |
| Earnings Before Tax Margin | 0.22 | 0.22 | 0.24 | 0.22 | 0.12 | 0.19 |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 |
|---|---|---|---|---|---|---|
| Revenue | 370.42 Million | 349.1 Million | 314.99 Million | 1.11 Billion | 266.85 Million | 294.42 Million |
| Cost of Revenue | 84.32 Million | 95.51 Million | 63.55 Million | 223.27 Million | 63.35 Million | 60.24 Million |
| Gross Profit | 286.09 Million | 253.59 Million | 251.43 Million | 893.36 Million | 203.5 Million | 234.17 Million |
| Operating Expenses | 217.69 Million | 191.92 Million | 175.95 Million | 872.73 Million | 234.39 Million | 175.19 Million |
| Selling, General and Administrative Expenses | 219.37 Million | 142.48 Million | 136.51 Million | - | 44.29 Million | 160.16 Million |
| Research and Development Expenses | 79.19 Million | 48.94 Million | 54.18 Million | - | 69.72 Million | 62.02 Million |
| Other Expenses | -80.88 Million | -490.76 Thousand | -129.7 Thousand | -872.73 Million | -234.39 Million | 59.15 Thousand |
| Cost and Expenses | 302.01 Million | 287.43 Million | 239.51 Million | 872.73 Million | 234.39 Million | 235.44 Million |
| Operating Income | 71.96 Million | 61.66 Million | 80.22 Million | 243.9 Million | 32.46 Million | 66.74 Million |
| Interest Expense | 796.43 Thousand | 1.2 Million | 976.42 Thousand | 3.41 Million | 923.64 Thousand | 921.44 Thousand |
| Income Tax Expense | 1.38 Million | 7.88 Million | 5.08 Million | 15.06 Million | -2.68 Million | 4.6 Million |
| Earnings before Tax | 71.91 Million | 78.67 Million | 80.09 Million | 243.8 Million | 32.34 Million | 66.79 Million |
| Net Income | 70.53 Million | 71.48 Million | 75.01 Million | 226.57 Million | 32.85 Million | 62.19 Million |
| Earnings Per Share Basic | 0.40 | 0.28 | 0.63 | - | 0.27 | 0.52 |
| Earnings Per Share Diluted | 0.40 | 0.28 | 0.63 | - | 0.27 | 0.52 |
| Weighted Average Shares Outstanding | 175.44 Million | 257.89 Million | 119.06 Million | 119.88 Million | 120.5 Million | 119.6 Million |
| Weighted Average Shares Outstanding (Diluted) | 175.44 Million | 257.89 Million | 119.06 Million | 119.88 Million | 120.5 Million | 119.6 Million |
| Gross Margin | 0.77 | 0.73 | 0.80 | 0.80 | 0.76 | 0.80 |
| EBIT Margin | 0.20 | 0.24 | 0.26 | - | 0.11 | 0.22 |
| Profit Margin | 0.19 | 0.20 | 0.24 | 0.20 | 0.12 | 0.21 |
| EBITDA | 72.7 Million | 83.08 Million | 80.4 Million | - | 30.47 Million | 64.84 Million |
| Earnings Before Tax Margin | 0.19 | 0.18 | 0.25 | 0.22 | 0.12 | 0.23 |
SBW
HGYN
6692
200541
600789
1171